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Although psoriasis is characterized by the accumula-
tion of activated proliferating lymphoid cells in the 
psoriatic skin lesion, it is not known whether these 
cells are activated and proliferating before entry into 
the psoriatic plaque. The current study evaluates the 
nU1Tl.ber and phenotype of proliferating lymphoid 
cells in the blood of psoriatic patients. Proliferation 
of peripheral blood mononuclear cells was evaluated 
on cytospun preparations of these cells using autora-
diographic techniques after pulsing the mononuclear 
cells 'With 3H -methyl thymidine for 2 h. The pheno-
I types of the labeled peripheral blood mononuclear 
cells 'Were determined combining autoradiography 
and hnmunohistochemistry with monoclonal anti-
bodies directed at CD3, CD4, CDS, CDllc, CD22, 
and human leukocyte antigen-DR. The data demon-
strated elevated numbers of proliferating lymphoid 
cells in the blood of psoriatic patients compared with 
, nOr1Tl.al nonpsoriatic volunteers (p < 0.01). Further-
A ctivated lymphoid cells appear to playa central role in the generation and maintenance of psoriatic skin les io ns [1]. It is hypothesized that lymphoid cells emigra te into the psoriatic plaque, become acti.vated , begin to proliferate and produce cytokmes In the 
psoriatic lesion [1-3]. AJthough activated lymphoid cells are found 
in the psoriatic plaque , it is not known whether some of these 
lymphoid cells are activated and proliferating before entry into the 
psoriatic plaque. 
Several lines of evidence suggest that activated lymphoid cells at 
nons kin sites m ay be important in genera ting or maintaining the 
psoriatic skin lesions. Although cyclosporin A therapy is quite 
effective w hen administered systemically, it is not effe ctive when 
injected into psoriatic lesions at levels achieved during systemic 
therapy [3,4] . Methotrexate (MTX) is another excellent therapy 
when administered sys temica IJ y [5- 7] but is not effective w hen 
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more, the number of circulating proliferating mono-
nuclear cells increased significantly with increasing 
psoriasis skin disease severity (correlation coefficient 
0.95; p < 0.0001). When the phenotype of the prolif-
erating cells in the blood was examined, the numbers 
ofT cells (CD3+, CD4+, CDS+ cells), B cells (CD22+ 
cells), monocytes (CD11c+ cells), and human leuko-
cyte antigen-DR + cells were significantly elevated 
compared with nonpsoriatic skin (p < 0.01) and in-
creased with increasing disease activity (correlation 
coefficient range 0.4S-0.74; p < 0.05). The data 
suggest a generalized systemic activation ofT, B, and 
monocytic cells that results in labeling of up to 0.16% 
of the circulating mononuclear cells with 3H-methyl 
thymidine (i.e., proliferating and presumably acti-
vated) when assayed ill vitro. Key lVords: pl'oiijemtioll/ 
activation/ 1)1l11p/wcy tel III et/w tl'exate. ] 111 vest Del'lllato 1 105: 
733-738, 1995 
delivered topically or intralesionally at concentrations that exceed 
those achieved during sys temic th erapy of pso riasis [8 - 13]. These 
data suggest that systemically administered cyclosporin A and MTX 
m ay be working at sites other than direc tly in the skin. Altho ugh 
the systemic immune system has been suggested as a potential target 
for these drugs , no changes in the peripheral bloo d m o nonucl ear 
cells (PBM C) have been found to correlate w ith clinical response . 
If activated lymphoid cells at nonskin sites are invo lved in 
generating o r maintaining psoriatic lesions, there should be eJe-
vated numbers of proliferating lymphoid cells in the blood of 
psoriatic patients compared with norma l individuals. T hese prolif-
erating lymphoid cell s that are not located in the skin could be a 
target of MTX therapy. In the current study, we quantified the 
numbers of spontaneously proliferating (i.e., activated) mononu-
clear cells in the blood of psoriasis patients and normal controls and 
correlated these numbers with the severity of pSOl;asis. 
MATERIALS AND METHODS 
Patient Selection Normal voluntee rs and psoriatic patients selected for 
this study were screened to eliminate individ uals who had a history of any 
febril e illness in the preceding month o r were taking systemica lly adminis-
tered steroids , beta blockers. o r anti malarial medications. T he psoriatic 
pa tients w ho were se lected had been using o nl y emollients or mid-strength 
topi cal steroids, but no ultra violet I3 (UVI3). psora len plus UVA. MTX . 
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retinoid. or cyclosporin in the preceding 2 111011th5. Psoriasis severity was 
evaluated using the psoriasis area and severity index (PASI) and the 
percentage of the skin surface area covered by psoriatic plaques by applying 
the rule of 9's [1 4]. Patients and normal volun teers were enrolled in tlus 
stud y after giving informed consent. 
PBMC Isolation Freshly dmw n venous blood was co llected in ethylene-
diaminetetraacetic acid tubes, mixed with equal amounts of Dulbecco's 
phosphate-buffered saline (Irvine Scie;,tific, Santa Ana, CAl, layered on 
Histopaque- l 077 (Sigma Diagnostics, St. Loui s, MO), and centrifuged for 
25 min at 400 X g. T he PBMC were collected, washed, and resuspended in 
4.0 ml of 30DC RPM I 1640 medium (Irvine Scientific). 
4-h Thymidine Incorporation Assays DNA-synthesizing PBMC were 
quantified by meas uring the aillount of tritiated thynlidine incorpora ted into 
2 X 10' PBMC during a 4-h incubation immediately after isolation. 
Mononuclear ce ll s (2 X 10' ) were added to 96-well plates and incubated 
with 4 ""Cilml ' H-methyl thynudine in 0.2 em' for 4 h. The cell s were 
harvested with a Titertec Cell Harvester on Skatron Filters and washed 
extensively. T he filters were placed in scintillation vials containing Ecoscint 
scinti ll ation fluid and were counted in a Beckman LS-3801 liquid scinti ll a-
tio n spectrometer. Controls included isotope-containing well s to verify that 
w"slung procedures were adequate to remove all free isotope. 
PBMC Labeling and Preparation for Autoradiography T he PBMC 
were adjusted to a concentration of approximate ly 3 milljon cells/ml and 
mixed 1:1 with RPM I 1640 containing either 8 J.LCi/ml of thymidine 
CH-TdR) (NET-027X thymid ine, [methyI-' H]-, specific activity 20.0 
C i/ mmol, concentration 1.0 mC i/mI, 0.05 ""mol/ml, 0.012 mg/ ml; NEN, 
DuPont Co. , W ilmington, DE) or, in one set of studies examining 
MTX-treated ce ll s, 16 ""Ci / ml of deoxyuridine (NET-l64 deoxyuridine, 
[6-' H]-, specific activity 1.0 TBq/ mmol, 27.7 Ci/ mmol, concentration 37 .0 
MBq/ ml, 1 .0 mCi/ ml , 0.036 ""mol/ml, 0.0082 mg/ml; NEN, Dupont Co .). 
This cell suspension was incubated for 2 h at 37DC in a 5% CO2 incubator 
and washed twice. After labeling, 5 X 105 cells were spun onto glass slides 
using a cytocentri fuge (Cytosp in 2; Shandon Inc., Pittsburgh, PAl, imme-
d iately fixed with a 1:1 acetone/methanol solu tion for 90 -1 20 seconds, and 
then placed in a Tris buffer. 
Immunohistochemistry The slides containing the PBMC were incu-
bated for 20 min at room temperature with blocking (horse) normal serum 
(1 :66 d ilu tion) from the Vectastain ABC Kit (Vector Labs, Inc., Burl-
ingame. CAl in T ri s buffer. The slides were incubated in a humidified 
chamber at 4DC overnight with the fo llowing primm" antibod ies (from 
DAKO A/S, Carpin te ria . CAl: CD3 monoclonal mouse anti-human T cell 
(DAKO-T3). CD4 monoclona l mouse anti-human T-cell helper/ inducer 
(DAKO-T4), C D8 monoclonal mouse anti-human T-ce ll suppressor/ 
cytotoxic (DAKO-T8). CDl l c monoclonal mo use anti-human protein 
150,95 (DAKO-P150 ,9 5) , CD22 monoclonal mo use anti-h uman B cell 
(DAKO-C D22), human leukocyte antigen (HLA)-DR monoclona l mouse 
anti-human (DAKO-HLA-DR). and IgG2a isotypc control. T he presencc 
of these monoclona l antibod ies (MoAbs) was assayed with the ABC Kit 
(Vector Labs). using the 3-amino-9-ethylca rbazole chromogcn and hyd ro-
gcn peroxide . 
Autoradiograph y Stained slides we re coated with 40DC-type NTB-2 
Kodak autoradiograph y emulsion (Eastman Kodak Co., New Haven. CT) 
and incubated at 4 DC (6 d in the stud y not using imm unohistochemistry, 
and . when combincd with immunohistochemistry: 27 h for thymidine. 43 h 
for dcoxyuridinc) . Slidcs were developed with Kodak developer D-19 
(Eastman Kodak Co .. Rochester. NY) and fixed with Kodak Rapid Fixer 
with Hardencr (Eastman Kodak Co. , R ochester. NY) . Slides were then 
washed for 15 min. dried. and mounted with glycerol gela tin (S igma 
Chcmica l Co. ). Active uptake of thy mid inc and deoxyuridine by the PBMC 
was determined by counting the cell s containing dark grains (positive cells 
have more than ·10 gra ins pe r ce ll) centered over the cell 's nucleus in a dense 
circular pattern . The prcsence or absence of the cell-associated red stain 
(positive immunohistochemistry) under the dark grains (positive autora-
diography) was cva luated . 
RESULTS 
Examination of PBMC Proliferative Capacity III Vitl'o T h e 
first studies exam ined the abi li ty of 2 X 105 PEMC isolated &om 
the blood of 13 norma l volunteers and 11 psoriasis patients to 
incorporate spontaneously 3H_ TdR during a 4-h incubation imme-
diate ly after isolation . T he rationa le for studying PBMC immedi-
ate ly afte r isolation was to maximize the chance of observing the 
amount of ill l) illD proli fe ration and to minimize the effects of ill vitro 
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PSORIASIS SEVERITY (PASI) 
Figure 1. PAS I versus PBMC. Psoriasis severi ty (PAS I) and the number 
of prolifcrating mononuclear ce ll s in the blood of psoriatic patients (labeled 
cells per million peripheral blood lymphocytcs [PBL]) are significantly 
correlated (correlation coefficient 0.95, P < 0.0001). 
culture. T h e m ean incorpo ration (± SD) was 352 ± 102 cpm in 
n ormal contro ls and 657 ± 259 cpm in psoriatic patients. T hese 
levels of isotope incorp o ratio n were statistically different (t test, p = 
0.003). T h e psoriasis patients h ad a mean PASl psoriasis severity 
score of 18 (PASI range 2.3- 50) . T h e severity of psoriasis (PAS I) 
and 3H-TdR incorporation were found to be signifi cantly corre-
lated, w ith a correlation coefficient of 0.70 (p = 0.018, N = 11). 
These data demonstrate th at PEMC isolated from psoriatics incor-
pOl'ate more 3H-TdR into DNA th an d o PEMC from 110 rmal 
individuals, and as the severity of disease increases , more 3H _ TdR 
is in corporated during a 4-h pulse with 3H_ T dR. 
It w as not clear from the above d ata w h eth e r there are more cells 
proliferating in pso ri asis than in n o rm al contro ls. It is possible that 
e qual numbers of PEMC pro liferate in n orm als and p sori atics bu t 
th at psoriatic PEMC pro liferate more rapidly th an n o rmal PEMC. 
To examine thi s point and prove tha t more cells are proliferating in 
p soriatics, we incubated PEMC from 11 n o rmal vo lunteers and 11 
psoriati c patients (mean PASI 12, range 1 .8 -28; m ean body surfa ce 
are a [ESA] 17, ran ge 1- 58) w ith 3H_ TdR. T h ese were cytospun on 
slides, and th e numbe r of cell s labeled with 3H _ TdR was de ter-
mined au torad iographica lly. The numbe r of labe led (i.e ., prolifer-
ating) ce ll s per m illio n iso lated PEMC was 203 ± 98 in n ormal 
volunteers and 823 ± 439 in psoriatics. T he fourfold e levation in 
proliferation in psoriatic p atients was signifi cantly different com-
pared w ith norm al n onpsoriatics (p < 0.0001). The severi ty of 
psori asis and the numbe r of labeled cell s per mi llio n PBMC were 
fou n d to be sig nifi cantl y corre lated, w ith a corre lation coefficient of 
0 .95 for th e PASl score (p < 0.0001, N = 11) (Fig 1) and a 
correlation coefricie nt of 0.88 for BSA (p < 0.0001). Patients with 
the m ost severe disease h ad approxim ate ly 1600 lab e led cell s/ 106 
PEM C (i.e., 0.16'X, of the iso lated PEMC), compared with 100 - 200 
labe led ce lls/ l0(' PBMC (i.e ., 0.01 % to 0 .02"/., of the isolated 
PEMC) in normal in dividuals. 
Phenotype of Proliferating PBMC T h e phen otype of the 
proliferating PBMC isolated &om the blood was evaluated in 
psoriatic patients and n orm al volunteers (Table I). For each 
phe notype, th ere was a signifi cantly high e r number of 3H-TdR-
labeled (proliferating) T cell s (CD3, CD4, CD8), B cells (CD22) , 
m acrophages (CDllc), and H LA-DR-positive ce ll s in the blood of 
psoriatic patients compared wi th normal individuals. T his diffe rence 
in the number of proliferating ce ll s was significant regardless of 
w h ethe r o ne normalized the number of proli ferating cell s per 
m illion isolated m on o nuclear cell s, p er milli lite r of b lood iso lated, 
or pe r mi ll ion of the studied phenotype. T he higher number of 
proliferating T cell s (CD3 + , CD4 +), E ce ll s (CD22 + ) , and mac-
roph ages (CD11 c +) found in psoriatics was n ot explain ed by 
differences in th e percentages of the ce ll types fou nd w h en the 
whole mononuclear populations in contro ls and p soriatics were 
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Table I. Elevated Numbers of Proliferating T Cells, B Cells, and Macrophages in the Peripheral Blood of Psoriatic 
Patients Compared With Normal Volunteers" 
Number Proliferating/ lOG PBMC" Number Proliferating/ ml Blood" Number Proliferating/ l 0" MoA bC 
Cellular 
Marker Normal Psoriasis p" NOfl11 a l Psori asis p Nannal Psorias is p 
Total" 194 ± 60 (20) 443 ± 290 (23) 0.0007 330 ± 152 897 = 622 0.0003 
CD3 56 ± 24 (19) 176 ± 121 (20) 0.0001 99 ± 56 357 = 238 0.0001 81 = 34 260 ± 190 0.0003 
CD4 35 ± 19(9) 113 ± 89 (19) 0.0017 61 = 31 228 = 168 0.0003 85 = 51 254 = 189 0.0016 
CDS 27 = 20(11) 93 ± 84 (21) 0.0048 47 = 40 183 = 153 0.0015 114 = 124 347 = 276 0.01 
CDllc 45 ± 27 (10) 11 2 ± 81 (23) 0.0031 84 = 68 219 = 159 0.0025 344 = 232 601 = 393 0.036 
CD22 56 = 23 (15) 129 ± 90 (23) 0.0014 98 = 57 263 = 187 0.0005 245 = 102 642 ± 434 0.0005 
HLA-DR 52 = 27 (18) 174 ± J 24 (23) 0.0002 98 = 66 366 ± 259 0.0009 203 ± 106 629 = 500 0.0001 
t l Proliferating PBM C were labeled with a 2-h -' H-TdR pulse. O n cytospin preparations of the labeled cells. first the phenotype was determin ed using immunohistochemistry. 
and o n the same specimen tb e pro life ratin g cells w ere identified autoradiographicall y (see IV/aleria/s lI lld l\t1etlwds) . 
I. Nun,ber of pro liferating P13M C of rhe indicared phenotype per miUion PBM C isola ted fro 111 the blood. o r {he Humber of pro lifcrllting PBM C of the indicated pheno type per 
rnHliliter of collected blood. The number of patients in the slllllple is indi ciltcd to the right of the mean ~ SO. 
c Nurnber of pro liferating PBM C of the illdicated phenot)'pe (cellular marker) per million of the indicated phcllorype: e.g .. number of pro li ferating C D3+ cells per million CD3 + 
in the isolotcd PBM C ± SD. 
t/ Significance level for t tes t cornparin g normal volunteer and psoriati c proiifer:1ting cell llllmhers. Psoriasis populatioll Ch.lrilcteristi cs: Illeil ll PASI 12.2: mean BSA involvell1ent 
17.6% . 
~ TotaJ number o f prolifcrilting PJ3M C ill normal volunteers and psoriasis patients. 
compared (Table II). The same percentages of CD3 + and CD4 + 
cells vvere found in the blood of normal individuals whether they 
were evaluated by Auorescence-activated cell sorter (FACS) ana l-
ysis at the V.A . Medical Center, Long Beach, California (laboratory 
nonna l values: CD3 + 70% ± 7%, CD4 + 43% ± 6'Yo) or by 
immunohistochemistry in this study (Table II). In summat-y, the 
data suggest that there is a generalized activation in psoriasis of a 
small population (up to 0.16%) of mononuclear cells that includes 
a diverse group of different phenotypes. TIllS increase in prolife r-
ating cells in psoriatics is not explained by gross changes in the 
numbers or percentages of each phenotype. 
The number of proliferating cells of the various phenotypes also 
correlated with the severity of psoriasis (Table III). The data 
demonstrate that the number of proEferating T cells (CD3, CD4, 
and CDS), B cells (CD22), macrophages (CDll c), and HLA-DR + 
cells correlated with psoriasis disease activity (PASI) , and the 
number of cells increased with more extensive disease . When the 
, entire population of mononuclear cells was examined , the percent-
ages ofT cells, B cells, macrophages, and HLA-DR + cells found in 
the blood of these psoriasis patients did not correlate with disease 
activity. Similarly, the total number oflymphoid cells per milliliter 
of blood did not correlate with disease activity (daca not shown). 
Table IV shows that there were more proliferating T cells in 
psoriatics than in normal nonpsoriatic volunteers when correcting 
for the absolute amount of proliferation . Equivalent percentages of 
labeled B cells and macrophages were seen when the data in Table 
I were normalized for the total amount of proliferation. The data in 
Table IV suggest that if cells of the normal volunteers had been 
activated to a degree similar to that found in psoriasis, there would 
be the same number of proliferating cells as in the psoriatic patients. 
A pathologic situation appears to occur in psoriasis that leads to 
more T-cell activation in psoriasis than in norm al indiv iduals 
regardless of the absolute number of proliferating cells. 
Although gross differences in the percentages of the entire 
population of CD3 + cells, CD4 + cells , CD22 + cell s, or CDllc + 
cells do not explain the elevation in the numbers of proliferating 
cells seen, e levated percentages of the whole CDS + cell population 
in psoriatics (Table II) might explain the observed increase in the 
number of proliferating cells (Table I). Similarly, the total percent-
age of CDS + cells isolated fi·om psoriatic PBM C and PASI were 
significantly correlated (R = 0.65 , P = 0.02, N = 12), and a higher 
percentage of CDS + cells was isolated as disease severity increased. 
These gross changes in the entire CDS + cell population might 
explain the correlation between proliferating CDS + cells and 
disease ac tivity. There was 110 correlation between disease ac tivi ty 
(PAS I) and the percentages of CD3 + cells , CD4 + cells, CD22 + 
cells, CDll c + cells , or HLA-DR + cells in the PBMC isolated fi·om 
psoriatics (data not shown). 
Proliferating Mononuclear Cell Number in the Peripheral 
Blood of Psoriatic Patients Mter Initiating Therapy of 
Psoriasis Preliminary results are presented in Table V examin-
ing the number of proEferating PBMC in three psoriasis patients 
before and after therapy with etretinate, UVB, o r MTX. The 
number of proliferating PBMC per million PBMC decreased 
significantly (p < 0.01) witllln 2-3 weeks after starting therapy and 
before the psoriasis skin lesions had a chance to respond to the 
therapy. A decrease in proliferating cell number also preceded 
Table II. Phenotype of Psoriatic and Normal PBMC Without Regard to Proliferative Status: No Dramatic Differences 
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• Phe notype of the isolotcd PBMC thot were CytoSpllll onto slides (C D + / fi eld)/(toco' cells / field). This phenotype is determined CVOlllO t1 ng all isolated cells per high-po wer 
microscope ficld. Because the percentages ofCD3 :md CD4 are the same as the Ilonnll i labora tory values at the V.A. Medic,,1 Center. Long Bench. C A. llIeasured by FA CS mlillysis 
(see text) , the techniques used to determine the phenotype of the cells ill this study appear 1'0 be as sensitive ;HId specific as FA CS analysis. 
b Phenotype of the PBMC determined llsing MoAbs to cell surf.,cc markers. which were detected Ilia inll1lullohisrochcl11istry. 
~ Statistical significancc for t tcst comparing the means of the percclltilges in normal volullteers and psol'iiltic patients. Th e Ilumber ill each s:lmple for each group is indicnted 
in the la s t column. 
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Table III. Phenotype of Psoriatic Proliferating PBMC: Correlation of Psoriasis Severity (PASI) With the Number of 
Proliferating PBMC" 
Number Proliferating/ Number Proliferating/ Number Proliferating/ 
10" pBMC ml Blood 10" MoAb Number 
Cell in Each 
Type R p R P R P Group 
C03 .67 0.003 .56 0.016 .63 0.006 18 
C04 .65 0.009 .57 0.025 .62 0.014 15 
C08 .68 0.015 .67 0.01 8 .65 0.022 12 
COllc .60 0.009 .48 0.040 .47 0.051 18 
C022 .65 0.004 .48 0.040 .55 0.01 8 18 
HLA-OR .84 0.0001 .74 0.001 .70 0.001 18 
Tota l .73 0.001 .60 0.009 18 
" Lin ear regress io n corre la tion cocfJicicnr (R) comparing the number of pro li ferati ng cells isolated in PllM C versus the psoriasis severity (PAS I). N in th e last column represents 
the !lumber of patients included in the regression nnalys is, <I ud the corresponding p value fo r the lin ear regression an~d ys i s is shown. Linear regression corre l:1rion coefficient and 
p arc shown for the corre lation of the number of pro liferating PBM e o f th e indicated phenotype/ l 0(' PBMe. th e number of proliferating PBMe of the indicated phcllotypchnl 
blood. and the number of pro li ferat ing PBM C ofth c indi ca ted phcnotype/ 'I 0(' of that SlI llle phenotype (c.g. , number of prolifc r:llin g CD3/ I 0(' CD3) versus psori:l sis severity (PASI). 
improvem ent in arthriti s in the patients treated with UVB and 
e tretinate. T he decrea ses in the number of proliferating PBMC 
were maintained as psoriasis severity improved, to at least 9 -11 
weeks. 
DISCUSSION 
Psoriasis is a di sease characterized by a hyperpro liferative epide rmis 
associated with the accumulation of activated prolife rating lym-
phoid cells in the dermis and epidermis of the psoriati c skin lesion 
[1] . Studies have demonstrated that activated lympho id cells in the 
psoriatic plaque are composed of HLA-DR + T cells , inte rleukin-2 
receptor+ T cells, and proliferating T cells [1-3]. The recruitment 
of lymphoid cells from the blood appears to be an important early 
step in inductio n of the psoriatic skin lesion, and ongoing migration 
of lympho id cell s £i'om the blood in to the psoriatic lesion may be 
involved in maintaining the psoriatic plaque [1]. It is not known 
whether these lymphoid cells are activated be fore entry or become 
activated after entry into the psoriatic plaque. Kastele r ef 11/ [15] 
demonstrated elevated numbers of HLA-DR + and interleukin-2 
receptor + T cells in the peripheral blood of patients with severe 
psoriasis compared with norm al controls. T he results in this study 
also demonstrate an increased number of prolifera ting (i .e., acti-
vated) PBMC in psoriatic patients compared with normal controls. 
T his study found not only that the number of proliferating lym-
phoid cells correlated significantly with psoriasis disease severity , 
but also that the numbe r of proliferating cells correlated with 
disease activity in patients having mild to moderate psoriasis. Based 
o n this information, one can hypothesize that at least som e of the 
Table IV. Phenotype of Proliferating Psoriatic PBMC: A 
Higher Percentage of the Circulating C03 + T Cells and 
COS + T Cells Are Proliferating in Psoriatics Than 
Normal Volunteers After Taking into Account the Total 
Amount of Proliferation 
Percentage of Total Radiolabc1cd Cells" 
Cellular 
Marker" Normal Psoriasis p" 
C03 31 ::':: 9 40 ::':: 9 0.003 
C04 23 ::':: 17 28 ::':: 8 0.39 
C08 17 ::':: 8 26::':: 8 0.008 
COllc 24 ::':: 8 25 ::':: 10 0.78 
C022 26 ::':: 6 30 ::':: 10 0.14 
"The percentage of total radiolabcJed cell s equals the number of radial abel cd PI3M C 
of the indicated phenotype ("cellubr marker") per 0.5 X 10(' PIJM C div ided by the 
total number of radio labcled cells per 0.5 X 10(' Pl3M C t imcs 100. 
/, Phcnotype of the PBMC determined using MoA bs to ce ll surface markers, which 
were detected J/ i a immunohistochemistry. 
r Statistical signifi cnnce fo r t test compllring the means of the percentages in normal 
volunteers and psoriatic patients. The number in each sa mple fo r each g roup is 
indicated in th e last column o n the right of T .. blc II. 
re levant lymphoid cells that initiate and m aintain the psoriatic 
les ion may alread y be activated before entry into the psoriatic 
lesion . It is possible, however, that the psoriatic les ion may generate 
the proliferating lymphoid cells found in the blood. Because 
elevated numbers of proliferating B cells are found in the blood of 
psoriatic patients but not in psoriatic lesions, tllis suggests that 
abnormal proliferation of mononucl ear cells m ay take place in 
lymphoid ti ssue such as the lymph n odes and spleen . 
The tota l number of 3H_ TdR-labeled lymphoid cells in the 
blood ofpsoriatics detected in this study represented a m aximum of 
about 0 .1 6'Vo of the circulating mononuclear cells in severe psoriasis 
and o nly a portion of all the pro liferating cells . The tota l number o f 
proliferating cells de pends o n the duration of S phase and the cell 
cycle time. If one assumes that the rapidly proliferating lymphoid 
cells are doubling about every 36 h (range 24 - 48 h) and have an S 
ph ase of about 12 h (range 8 -1 6 h) , then the number of labeled 
cells de tected in this study would represent about one third of all 
Table V. Effect of Therapy on the Number of 
Proliferating Mononuclear Cells Found in the Blood of 
Three Psoriatic Patients, and Correlation With the 
Clinical Response to Therapy 
Weeks After Psoriasis 
Starting Severity 
Therapy Therapy" Labeled PBMC" (PAS I) 
Methotrexate' 0 786 ::':: 85 5.9 
2 354 ::':: 64" 5.9 
4 232 ::':: 76" 3.6 
7 86::':: 57" 2.2 
UVB" 0 653 ::':: 77 23 
2 487 ::':: 71 " 23 
5 344 ::':: 72,1 22 
11 461 ::':: 61" 14 
Etretinat'! 0 338 ::':: 82 10 
3 88 ::':: 65" 10 
5 79 ::':: 43" 5.S 
9 6 ::':: 4" 5.5 
" Zero weeks is the prc therapy evaluation . 
/' N umber of labeled PBM C per 10(, PBM C isolated fro m the blood of the psoriasis 
patie lHs :t SO. J I-I_ TdR. w as used to label the UVB and etrctinatc patient samples; 
' H-Ud R wos used to label the MTX potiellt samples (sec Male,;"I, nlld Meilwds) . 
( MTX administered o rall y every 12 h for a tota l o f three doses once per week. Total 
weekly dose at indicated time: week 2. 5 mg tota l (2.5/2.5 / 0); weck 4, 7.5 mg total 
(2.512 .512 .5); week 7. '10 mg total (512.512 .5). 
d Comparison w ith prcthcrapy level (week 0) signific;l11ti y different w ith t test: p < 
0.0 1. 
I· UVB ligh t therapy. Total number of treatmen ts and to t:11 light dose were as 
fo ll ows: wcek 2. five treatments, 3 mJ /cm 2; week 5, 13 trea tmclHS, 21 I11J /C I112; week 
11 .20 treatments. 47 I11J /C Il12. 
JEtretinatc therapy adrninistcrcd fo r the first 3 weeks at 40 mg/day. and fro m weeks 
5-9 at 30 mg/dny. 
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proliferating cclls, o r about O.4S% of circulatin g PBM C [1 6] . Each 
ph e notype studied rcprcscn tcd only a po rtion , about 25°/., to 50%, 
of the tota l population being studicd, and thus O.l'Yu to 0.2% ofthc 
PBMC of a given phenotype would bc expected to bc pro liferating. 
The fre qucncies of PBM C that proliferate in rcsponse to so lublc 
antigens administcred ill lI i llo are similar to thosc reported in thc 
current study. Tn ba cillus Calmettc- G uerin-immunized individuals, 
th e nun'1ber of T cells that prolife ra ted in response to stimulation 
with purified protein derivati ve was 72-510/ 10(' T cells (i.e. , 
0.0072'Yu to 0.051% of T ce ll s) [17] . In tetanus-toxoid-il11mune 
individua ls who were boosted, the nl1lnbe r ofT cells that prolife r-
ated in r esponse to stimu lation with te tanus toxoid was S7-1333/ 
106 T cell s (i. e., o.OOSnl" to 0.1333% of T cell s) [l S). Sohnle and 
Collins-Lech [19] found the frequen cy of streptokinase/streptodor-
nase-reactive T cclls to be 44 - 909/106 (or 0.0044% to 0 .0909°;',) in 
inun. l.lne individuals . T he fi'cquency of T ce ll s in the pe ripheral 
blood that pro liferated before immunization with keyhole limpet 
hemocyanin was 2.9 - 6 .7110(' T cells, and after immuniza tion thcrc 
was a several-fo ld increase to 24-40/10(' T cells [20]. The sma ll 
number (less than 0.16'X" o r 1600/ 10" PBMC ) of pro life rating 
lymphoid cell s found in psorias is is consistent w ith an antigen-
driven process in immun e indi viduals ra the r than a potent superan-
tigen-drivcn process, in which 5% to 10% of the cells would be 
expect e d to be pro life ra ting [21] . A more limited activation of a 
smail n.umber of T ce ll s by a m ore sp ecific supcrantigen is also 
consiste nt with the current data . C hang (' f fli [22] recently dem on-
strated that lesional psoriatic C DS + T cells preferentially usc T - cell 
, receptor V {33 and/or V {313.1, where no such increase was noted in 
the p e ripheral bl ood. T he lack of correlation o f T - cell recepto r V {3 
expression in the pe riphe ral blood cOLLid refl ect the fact that only a 
very s ITlall re lev<l11t population of ce ll s is presen t and that after 
localiz ing to the pso ria tic les ion , they pro life rate and expand the 
re levan t T - ce ll population in such a way that it can be demon-
strated. T he e levated B-cell p ro ljfe ration found in psoriatics in this 
i study raises the possibility that rathe r than an antigen , a superanti-
gen is s timulating resting B cells and triggering their prolife ration 
[23]. Add itional studies will be req uired to resolv e these issu es. 
Previous studies examining the phenotyp e of the en tire circulat-
ing PBMC popul ation in pso ri atics ha ve not found consistent 
changes. Som e studies exa mining the PBM C fi'om patients with 
mod erate to severe psoriasis (20% to 40% BSA) have reported 
decrease d numbers of C D3 + cells, CD4 '" ce lls, and C DS ·1- cells 
[24,25]. O ther studies found no difFerence in the numbers o r 
percent ages of C D 3 + cells, C D4 + cells, and HLA-DR ·1· ce lls in the 
blood of psoriatic compared with normal individuals [26,27]. In the 
present stud y, we observed no signifi cant diffe rences in the total 
num b el'S o r percen tages of CD3 + . CD4 -1- , CD22 " , o r C D11 c + 
cell s in th e peripheral blood . However, an eleva ted percentage of 
CD8 + ce ll s was detected compared with normal volunteers, and 
trus was proportional to disease severi ty. 
T he nlcchanism(s) by which MTX improves psoriasIs is not 
known. Although systemic administration of MTX is ve ry e ffec tive 
in treati.ng psoriasis [5-7], topical o r intrade rmal MTX. despite 
adeq u ate loca l de li ve ry into th e skin, is not an effective psoriatic 
the ra py [S-1 3]. This suggests that sites othe r than the skin may be 
importa nt in the m echan..i sm by which MTX improves psoriasis. 
Detailed ill lJ i/ro studies have shown that prolife rating lymphoid 
cells are kiJled e ffectively at the sam e levels of MTX achieved ill 
vivo [2 8 ] . Kaste ler el fli [15.1 , without showing data, reported that the 
percentages of HLA- DR+ and interleukin-2 receptor + cells in 
three patients w ith mild psoriasis treated with MTX were not 
different from those in three othe r pati ents not trea ted with MTX. 
Prelirninary data in the current study indica te that the elevated 
num b el' of pro liferating lymphoid cells in the b lood decreases in the 
same patien t afte r therapy is initiated with MTX, and this occurs 
befor e clinical improvem ent is seen. T he data demonstrating 
eleva t e d numbers of proliferating ce lls in a large group of psoriasis 
patients in this study also suggest that these prolife rating PBM C 
co uld b e a targe t of MTX during therapy of psoriasis . We thus 
postulate that activated proljfe rating lymphoid ce lls at nonskin sites 
may be an impo rtan t target of systemic MTX therapy in psorias is. 
T hese activa ted lymphoid cells coul d be killed by the well-
documented biochemi cal actions of MTX on pro life rating ce lls 
before they have a chance to mig rate into the psoriatic les ion [29]. 
If p ro liferating lymphoid cells in the blood of psoriatic patien ts 
arc relevant to m aintain ing disease activity, then othe r systemic or 
phototherapies may also decrease the number of circul ating proli f-
erating lympho id cell s. In prelimin ary expcrim ents here. one 
patien t trea ted with UVB and anothe r with etretinate both showed 
a decrease in the number of pro life rating lymph oid cell s before 
clinical improvement in skin and j o int disease was evident. Again , 
this suggests a ro le for circulating activated lymph oid cells in th e 
pathogenesis o f psoriasis. 
[n rheumatoid arthriti s, increased numbers of proliferatin g 
PBM C also ha ve bccn found using similar m ethodology [30]. T he 
number of prolife rating cells in severe ac tive rheumatoid arthritis 
was reported to be 310 pe r million PBM C (0.()31%). versu s 57 per 
million PB MC (0 .0057%) in n 0 n11al contro ls. Russell [30] found 
e levated numbers of pro life rating ce Ll s in both T and non- T 
populations , as havc other investigators [3 '\] . Ru ssell [30) m en tions 
in this ar ticl e, without showing the data , tha t :1 3 patients treated 
with MTX showed a decrease in the number of proli ferati ng PBMC 
fi'om 165/ 10" PBM C to 20/106 PBMC 2 d afte r rece iving 10 m g of 
MTX intramuscularly. In 12 patients receivin g m ore than 4 months 
of "remittive" the rapy for rheuma toid arthri tis othe r than MTX, 
the number of pro lifera tin g PBM C was lower in the trea ted patients 
than untrea ted patients with severe rh eum ato id arthriti s (133 / 10" 
versus 310/ 106 PBMC, respectively). T he phenotype of these two 
gro ups was compared. T he percentage of !-ILA-DR+ pro liferating 
cell s decreased from 61% to 34% w ith remitcive the rapy; h owever, 
the pe rcentage of pro liferating C D3 + ce ll s did not change w h en the 
untreated and trea ted rheum ato id arthri tis groups were compared 
(46% versus 42%, respectively). In othe r studies of patients w ith 
rheumatoid arthriti s undergoing the rapy with MTX, the tota l 
number and percentage of C D3 -1- , CD4 -1- , and C D S+ cells did not 
change significantly as the pat.ien ts improved clinically [32,33]. 
Although e lev'lted numbers of activated proliferatin g lympho id 
cells are found in the joints of rh eumatoid arthritis patients with 
activc disease [34] , local injection o f MTX in to the joints has not 
improved symptom s or decreased local disease activity [35]. T hus, 
the re appears to be a similari ty between psoriasis 'lIl d rheumatoid 
arthriti s in the blood and target end orga.ns o r in the responsiveness 
o r lack of response to systemic versus loca l MTX the rapy. 
T he hypo thes is o f activation of the immune system at sites distant 
to the targe t o rgan in psoriasis and in a number of re lated 
autoimmun e diseases he lps ex plain both the pathogenesis of other 
noncutaneous findings in pso riasis (e.g., psoriatic arthritis) and the 
reason why locally administered MTX docs not improve pso ri atic 
cutaneo us les ions and rhcu m atoid arthriti s j oints. In this m odel of 
psoria sis, the re m ay be immune activation in cen trally located 
lymphoid tissue such as lymph nodes and cven tu al circul ati on of 
activated lymphoid cells. Some activated T ce ll s o r other mononu-
clear cell s could localize to the skin o r the j o int to induce d isease in 
these sites. At these target tissue sites, the acti vated mononuclea r 
cells encounter the appropriate environm ent to becom e triggered 
to main ta in proliferation an d production of cytokines. 
T his /l!ork II las sllpported by n .f.!fflUI .Fol1l Ihe DCfllznfO/OS), FOll ll dnt io /l fwd tlte 
SeJII t//(!fI I Calij(}min Dermalolog}, FOlllldfltim1. 
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ANNOUNCEMENT 
T he First J o in t Meeting of the Japanese and Canadian Societies for Inves tigative D ermatology 
will be held M ay 31. June 1 and 2, 1996 at the Whistle r, Bristish Columbia , C anada. 
T he major theme will be "What can we learn and expect fi·om our studies of basic biology 
and molecu lar biol ogy of the skin? Current con cepts and application to new diagnosis and 
treatm ent approaches of skin diseases." 
The meeting is organized by the Canadian Society fo r Invescigacive Dermatology and 
Japanese Soci.ety for Investigative Dermatology. 
T here will be two pl enary sess ions, one clinica lly-oriented research small-group session, 
poster re views, and three workshops; Workshop 1 will be "Melanin Pigmentation and 
M alignant Melanoma," workshop 2 wi ll be "Genetic Analysis and G ene Therapy," workshop 
3 will be "Cytokines and dendricic cells," and sess ion 1 will be "Clinically-Oriented 
Resea rch ." 
For more information , abstract and registratio n forms please contac t JSID /CSID Adminis-
tratio n o fl:i ce. University of Alberta, D ermatology & Cutaneous Sciences Division, 260G 
H eri tage M edi ca l Research Centre, Edmonton , AD T6G 2S2 Canada; phone (403) 492-1875, 
fax (403) 492-7715 . 
